Novo Nordisk Stock Sinks After Semaglutide Fails to Slow Alzheimer’s Progression
Shares of Novo Nordisk fell sharply on Monday after the Danish pharmaceutical group disclosed that a pivotal study evaluating semaglutide for Alzheimer’s disease did not meet its primary endpoint. The decline took the stock to its lowest level since mid-2021, extending a sustained slide that has erased roughly half of the company’s market value since […]